ImageneBio dismisses EY, appoints PwC as auditor effective Aug 2, 2025

ImageneBio, Inc.

Audit committee dismissed Ernst & Young LLP as independent auditor effective August 2, 2025.
No disagreements or reportable events occurred during EY's audit periods (2024, 2023 and interim).
PricewaterhouseCoopers LLP appointed as new auditor for fiscal year ending Dec 31, 2025.
PwC previously served as auditor of Inmagene Biopharmaceuticals prior to merger with ImageneBio.
EY's audit reports for 2024 and 2023 were unqualified, with no adverse opinions.

item 4.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.